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RELEVANT PREVALENCE OF Mycoplasma hominis AND Ureaplasma urealyticum SEROGROUPS IN
HIV-1 INFECTED MEN WITHOUT URETHRITIS SYMPTOMS
Caio Mauricio Mendes CORDOVA(1) & Regina A. F. CUNHA(1)
SUMMARY
M. hominis and U. urealyticum are the better-known mycoplasma species pathogenic to the human genitourinary tract, causing
mainly urethritis, bacterial vaginosis and pregnancy complications. In HIV-infected patients, the prevalence and role of these species
is still not well known. The aim of this work was to determinate the prevalence of these species in this group of male patients (HIV
group), in comparison to a group of men with clinical symptoms of urethritis (STD group). M. hominis was isolated from 7.5%
patients (8/106) and U. urealyticum from 18.9% patients (20/106) from the HIV group, being among these 62.5% and 85% in
significant concentrations, respectively. In the STD group these rates were 0.9% (1/110) for M. hominis and 13.6% (15/110) for U.
urealyticum, being 100% and 93.3% in significant concentrations, respectively. We could demonstrate infection rates by these
mycoplasma species in the HIV group as high as the one found in the STD one, what may indicate the occurrence of opportunistic
infections in our population. This fact is discussed here because in immunosuppressed patients, specially M. hominis has been
reported causing severe infections, even systemically.
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INTRODUCTION
M. hominis and U. urealyticum are the better-known mycoplasma
species pathogenic to the human genitourinary tract. U. urealyticum is
one of the major causes of nongonococcal urethritis in men, being isolated
from about 12% of these cases7. It has also been reported causing
epididimitis, infectious kidney stones, sexually transmitted reactive arthritis
(Reiter’s Syndrome) and arthritis in hypogammaglobulinemic patients18.
In women, its role in the etiology of pregnancy complications is suggestive,
inducing pre-term labor, spontaneous abort, infertility, puerperal fever and
Pelvic Inflammatory Disease17. Transmission of U. urealyticum to the fetus
or newborn may cause severe broncopulmonar displasias, and even central
nervous system (CNS) infections1,6. However, a difference of pathogenicity
among it’s 14 serotypes has been reported, by frequency of isolation from
different clinical manifestations, as well as different in vitro properties4.
M. hominis may also cause urethritis in men, but in a lesser extension:
about 3-4% of the cases11. It is known as the most important agent of
bacterial vaginosis, being involved in Pelvic Inflammatory Disease, pre-
term labor, puerperal fever, and respiratory tract diseases in neonates,
infecting the CNS in some cases17.
In HIV-infected patients, the prevalence and role of these species is
still not well known. However, there have been several reports about M.
hominis systemic infections in immunosuppressed patients, sometimes
severe10, as well as for U. urealyticum5. Therefore, we decided to
investigate the prevalence of this species among HIV-1 infected patients
without symptoms of urethritis, compared to HIV-1 negative individuals
presenting these symptoms.
MATERIALS AND METHODS
Patients and samples: HIV Group: urethral swabs and urine samples
were obtained from 106 adult male patients infected by HIV-1, without
clinical symptoms of urethritis. In this group, CD4+ T cells could be
obtained from 58 (54.7%) patients. Six patients had CD4+ T cells lower
than 50/mm3 (10.3%), 26 between 50 and 250 (44.8%), 17 between 250
and 500 (29.3%), and 9 above 500 (15.5%). Patients with CD4+ T cells
count lower than or equal to 250/mm3 were receiving prophylactic
preventive therapy.
STD Group: urethral swabs and urine samples were obtained from
110 adult HIV-negative men attending a STD clinic, with symptoms of
urethritis. Patients under antibiotic therapy were excluded from this study.
In this group, 47 (42.8%) were infected with Chlamydia trachomatis, 7
(6.4%) with Neisseria gonorrhoeae, and 5 (4.5%) with other
microorganisms, including Staphylococcus aureus, Escherichia coli,
Enterococcus faecalis, Streptococcus spp., and Trichomonas spp.
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Urine samples were concentrated ten fold by centrifugation and, as
urethral swab samples, were maintained in 3 ml of A3XB modified transport
medium at 4 ºC for 2 hours at most until inoculation in culture media15.
Mycoplasma culture: from each sample in transport medium, 0.1
ml was inoculated in A7 solid media, and 0.5 ml in tubes containing 2
ml of Arginine broth, 2 ml of U10 broth, or 2mL of SP-4 broth16. From
each of these tubes, serial ten fold dilutions were made three times in
fresh media, resulting in culture of samples in final dilutions of 1:5,
1:50 and 1:500. Cultures were incubated at 37 ºC in 2-3% CO2 for two
weeks, with the exception of SP-4 cultures which were incubated under
aerobic conditions, for at least one month, with blind passages every
week to new tubes, and also replicated to plates with solid SP-4 medium.
Cultures with suspected M. fermentans growth were also incubated in
Glucose broth under anaerobic conditions, using the GasPack® System
and AnaeroGen™ gas generator (Oxoid Ltd., Basingstoke, Hamshire,
England).
Quantification of isolates: quantification of M. hominis and U.
urealyticum present in urethral swab samples was performed by the
microtitration technique, once this methodology is well standardized
for this kind of material16. Briefly, in a 96-well sterile plate, 30 µl of
sample in transport medium were incubated in 270 µl of broth media,
namely U10 for U. urealyticum or Arginine for M. hominis, and serial
ten fold dilutions from 10-1 were performed. The higher dilution which
changed the color of the indicator present in the broth represents the
number of microorganisms in the sample, in CCU (Color Changing Units)
for mL.
Mycoplasma identification: Sample preparation for PCR: samples
were treated according to the procedure described by BARBEYRAC et
al.2. Briefly, 1 ml of mycoplasma culture medium was centrifuged for
15 minutes at 13,000 x g, ressuspended in 0.5 ml of lysis buffer (1 mM
EDTA, 10 mM Tris-HCl, 0.1% Triton X-100, 200 µg/mL Proteinase K,
pH=8.0), incubated at 56 ºC for 60 minutes, and at 100 ºC for 10 minutes.
Samples were extracted with phenol and phenol/chloroform/ isoamylic
alcohol. DNA was precipitated with ethanol and dissolved in 100 µl of
T.E. buffer (1 mM EDTA, 10 mM Tris-HCl, pH=8.0).
M. hominis: identification of M. hominis was performed in samples
which changed the color of the indicator in Arginine broth and showed
typical Mycoplasma spp. colonies in A7 solid medium. Identification
was done by the Ouchterlony’s immunodifusion technique12 with
polyclonal anti-M. hominis rabbit serum (kindly produced by Dr. Célia
Otsuka Takiy, PROBAC, São Paulo, Brazil), and by the PCR technique8,
for which two µl of Arginine broth treated as described above were added
to the reaction mix. PCR was done in a final volume of 50 µl, with 1x
Taq Reaction Buffer (Pharmacia Biotech, Uppsala, Sweden), 25 mM
dNTP solution (Gibco BRL, Gaithersburg, MD, U.S.A.), 1 µl of each
primer at 30 µM (HOM+: 5'-tgc.acc.atc.tgt.cac.tct.gtt.aac.ctc-3' and UNI-
: 5'-act.cct.acg.gga.ggc.agc.cgt.a-3'), and 1 U of Taq DNA Polymerase
(Pharmacia Biotech, Uppsala, Sweden). Amplification included and
initial denaturation step at 95 ºC for 15 minutes, followed by 30 cycles
with denaturation at 95 ºC for 30 seconds, primers annealing at 58 ºC
for 1 minute and 30 seconds, extension at 72 ºC for 1 minute and 30
seconds, and a final extension step at 72 ºC for 10 minutes. PCR products
were detected by agarose gel electrophoresis at 0.8% with ethidium
bromide staining under U.V. light. As a positive control we used DNA
from the strain ATCC 23114 of M. hominis. The specificity of M. hominis
DNA amplification was evaluated by analysis of the PCR products
restriction patterns with the enzyme Kpn I, which yielded one fragment
of 299 bp and another of 290 bp.
U. urealyticum: samples that showed characteristic Ureaplasma
genus colonies in A7 solid medium and changed the color of the indicator
in U10 broth were tested using a specific PCR assay for U. urealyticum.
The procedure was the same described above for M. hominis, with
utilization of different primers (Uu3: 5'-gat.ggt.aag.tta.gtt.gct.gac-3' and
Uu4: 5'-acg.acg.tcc.ata.agc.aac.t-3'). Another set of primers (Uu1: 5'-
cac.aga.tgt.cct.tga.tgt.ac-3' and Uu2: 5'-cac.aga.tgt.cct.tga.tgt.ac-3'),
specific for U. urealyticum strains of biotype 2, was also used3. As positive
control of U. urealyticum biotype 1 and 2, we used DNA from the strain
ATCC 27618 of U. urealyticum and from a strain isolated in our
laboratory, respectively.
Statistical analysis: data obtained were analysed by the Fisher’s
exact Test, using the GraphPad InStat ™ software (San Diego, CA, USA).
RESULTS
M. hominis and U. urealyticum isolation and identification from
clinical samples
In the group of HIV-infected patients, 21/106 (19.8%) had a positive
culture for mollicutes, in urethral swabs as well as in urine samples (Table
1). From these, U. urealyticum was isolated in 20 (18.9%), and M. hominis
in 8 (7.5%). In the STD group, M. hominis isolation rate was lower
(0.9% [1/110]; p=0.02), but there were no significant difference with U.
urealyticum (13.6% [15/110]; p=0.37). All of the strains isolated with
presumptive identification of M. hominis were confirmed by the
Table 1
 Mycoplasma culture and identification in the HIV and
STD groups of patients
HIV group STD group
Isolation Relevant concentrations1 Isolation Relevant concentrations
M. hominis 8/106 (7.5%)* 5/8(62.5%) 1/110 (0.9%) 1/1(100%)
U. urealyticum 20 /106 (18.9%) 17/20(85%) 15/110 (13.6%) 14/15(93.3%)
1Relevant concentrations were considered ≥104 CCU/mL for U. urealyticum and ≥103 CCU/mL for M. hominis.
The statistical difference between the results obtained with the two groups of patients is indicated: *p < 0.05.
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fermentans or M. penetrans by culture failed, from both urine and urethral
swab samples of the HIV- infected and STD groups of patients.
Quantification of the isolates
In the HIV group, 62.5% of the M. hominis isolates were in relevant
concentrations (≥103 CCU/mL), and for U. urealyticum, this rate was
85% (> 104 CCU/mL). In the STD group, 100% and 93.3% of the M.
hominis and U. urealyticum isolates were in relevant concentrations.
DISCUSSION AND CONCLUSIONS
M. hominis and U. urealyticum are commonly found in the
genitourinary tract as the causative agents of several sexually transmitted
diseases. In men, U. urealyticum is one of the major causes of non-
gonococcal urethritis, which may also have participation of M. hominis
in a lesser extension17. In our work, we found a relevant prevalence of
these urogenital mycoplasmas in two groups of patients, HIV-infected
ones and persons presenting with urethritis. The higher rate of urogenital
mycoplasmas in the HIV group suggests at least two hypotheses. First,
the immune deficiency associated with HIV infection could be a
predisposing factor for mycoplasma urogenital infections. Because there
was no correlation between the detection of mycoplasmas and the CD4+
T cell number or the CD4/CD8 ratio in the HIV group (data not shown),
the immune deficiency predisposing to the mycoplasma colonization
must be an early event during the HIV infection. The second hypothesis
is that the increased frequency of mycoplasmas could be related to
homosexual/bisexual practices, hence its higher rate in some HIV-infected
patients, as suggested for M. penetrans previously by others19. This higher
frequency of urogenital mycoplasma infections in HIV-infected patients
may have a possible implication regarding the transmissibility of HIV.
Indeed, it has been shown that various STD, including the non-ulcerative
ones, can facilitate the sexual transmission of HIV13.
The fact that we could demonstrate a relevant rate of U. urealyticum
and especially a higher M. hominis infection rate in the HIV-1 infected
patients group, who presented no apparent symptoms of urethritis, is
very interesting and must be remarked by at least two aspects. In patients
with hypogammaglobulinemia or cell-mediated immune response
suppressed, especially M. hominis may have extragenital manifestations,
causing a great damage to the host, such as vascular, wound, joint, CNS
and respiratory tract infections10. In many of these patients, the ultimate
source of M. hominis infection was the genitourinary tract, but the
hypothesis that this microorganism may have hematogenous
dissemination or invasive disease by other routes must be taken in account.
An increased frequency of U. urealyticum and M. genitalium infection
rates in HIV-infected patients has also been recently reported by others,
with a similar rate of U. urealyticum infection (12.3%) as the one obtained
in our work9. Like M. hominis, this species has also been shown to
produce extragenital infections, specially in patients with antibody
deficiency, causing pneumonitis, sinusitis, cystitis, arthritis, osteomyelitis,
cellulitis and chronic sinopulmonary disease5. Thus, by the infection
rates observed in our study, these microorganisms may be playing a
more important role in HIV-infected individuals in our population than
the most part of clinicians and investigators currently suspect. Therefore,
its participation in some severe syndromes in this group of patients,
frequently not diagnosed, may be underestimated. Otherwise, even in
infections restricted to the genitourinary tract, we do not know if relevant
Fig. 2 - A: Identification of suggestive U. urealyticum isolates by PCR with primers Uu3 and
Uu4. Lanes 1: Positive control; 2: negative control; 3-6: samples which changed the color of
U10 broth culture tubes. B: identification of U. urealyticum serotypes belonging to biotype 2
with primers Uu1 and Uu2. Lanes 1: positive control; 2: negative control; 4, 6, 7, 8, 11, 12
and 14: positive samples; 3, 5, 9, 10 and 13: negative samples. Weight marker: 100 bp DNA
Ladder.
Fig. 1 - A: Identification of suggestive M. hominis isolates by PCR with primers HOM+ and
UNI-. Lanes 1: Positive control; 2: negative control; 3-8: samples which changed the color of
Aginine broth culture tubes. B: Restriction pattern of the amplified products by digestion
with the enzyme Kpn I. Lanes 1: Positive control not digested; 3, 5 and 7: samples not
digested; 2: digested positive control; 4, 6 and 8: digested samples. Weight marker: 100 bp
DNA Ladder.
Ouchterlony’s technique and PCR (Fig. 1), as well as for U. urealyticum
(Fig. 2). In the HIV group, 50% of the U. urealyticum strains were
distributed in each cluster (p=1.25), and in the STD group, 53.3% were
classified in the biotype 1 and 46.7% in the biotype 2 (p=1.00). Attempts
to isolate other mycoplasma species, including M. genitalium, M.

CORDOVA, C.M.M. & CUNHA, R.A.F. – Relevant prevalence of Mycoplasma hominis and Ureaplasma urealyticum serogroups in HIV-1 infected men without urethritis symptoms. Rev. Inst.
Med. trop. S. Paulo, 42(4): 185-188, 2000.
concentrations of a lesser pathogenic serotype of U. urealyticum is more
significant than a lower concentration of a more pathogenic serotype.
The extension of these pathogenicity differences among M. hominis
strains is still not known. Therefore, only studies including determination
of U. urealyticum serotypes or M. hominis strains differences may help
us to correctly evaluate their role in human diseases, specially in
immunosuppressed patients infections.
Furthermore, beyond the fact that the defective immune response of
these individuals may favour their establishment, these microorganisms,
mainly M. hominis, may be playing more relevant pathogenic roles even
in progression of AIDS disease. This can be hypothesised once they
have, at least in vitro, properties that can modulate the host immune
system14, such as arginine depletion, cytotoxicity toward lymphoid cells,
activation of monocytes and polymorphonuclear cells, induction of
cytoquines production, etc. However, the extend that M. hominis
interaction may have systemically in modulating the immune system is
still not known. As we can see, in spite of the evolution that science as a
whole could accomplish in the last years, there are several aspects in
human mycoplasma infections that remain unclear. We believe that the
prevalence and the role of these microorganisms in immunosuppressed
patients must be more extensively investigated.
RESUMO
Prevalência relevante de Mycoplasma hominis e sorogrupos de
Ureaplasma urealyticum em homens infectados pelo HIV-1 sem
sintomas de uretrite
M. hominis e U. urealyticum são as espécies de micoplasmas mais
conhecidas como patogênicas para o trato geniturinário humano,
causando principalmente uretrite, vaginose bacteriana e complicações
da gravidez. Em pacientes infectados pelo HIV, a prevalência e o papel
destas espécies ainda não está bem estabelecido. O objetivo do presente
estudo foi comparar a prevalência das espécies acima referidas na uretra
de pacientes masculinos portadores do vírus HIV (Grupo HIV) com a
prevalência das mesmas entre homens não portadores do HIV mas com
sintomas de uretrite (grupo DST). No grupo HIV, M. hominis foi isolado
de 7,5% pacientes (8/106) e U. urealyticum de 18,9% pacientes (20/
106) em concentrações significativas de 62,5% e 85% respectivamente.
No grupo DST estas taxas foram 0,9% (1/110) para M. hominis e 13,6%
(15/110) para U. urealyticum, sendo 100% e 93,3% em concentrações
significantes, respectivamente. Pôde-se demonstrar que no grupo HIV
as taxas de infecção por estes micoplasmas foram tão elevadas quanto as
observadas no grupo DST. Tais achados podem indicar a ocorrência de
infecção oportunista, o que, em pacientes imunocomprometidos
representa risco de desenvolvimento de infecções sistêmicas.
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